Prime Medicine, Inc.
PRME Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$3.67
KIRA · Stoqly’s AI analyst, in plain words
- Prime Medicine, Inc. had $4.6M of revenue in fiscal 2025, up 55.3% on the year before. Over five years, revenue changed −2.3% a year on average.
- Its operating margin was −4,498.1%, up 2,289.3 pts: of every 100 in sales, about −4,498 is left after running the business.
- Prime Medicine, Inc. lost $201M in fiscal 2025.
- Free cash flow was −$167M in fiscal 2025, −3,607.4% of revenue.
Market cap
$650M
P/E
—
Revenue
$4.6M
Net income
−$201M
Free cash flow
−$167M
Operating margin
−4,498.1%
Prime Medicine, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+55.3%
Yes. Sales grew 55.3% last year.
Does it make a profit?
−4,342.4%
No. It lost money last year.
Does profit turn into cash?
−3,607.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Prime Medicine, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Prime Medicine, Inc.
- CIK
- 0001894562
Prime Medicine, Inc. · PRME
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $3.0M | $4.6M |
| Revenue growth | −100.0% | — | — | — | 55.3% |
| Operating margin | — | — | — | −6,787.4% | −4,498.1% |
| Net income | −$165M | −$122M | −$198M | −$196M | −$201M |
| Net margin | — | — | — | −6,566.6% | −4,342.4% |
| Diluted EPS | −$14.19 | −$4.19 | −$2.18 | −$1.65 | −$1.35 |
| Cash | |||||
| Cash from operations | −$34.1M | −$132M | −$165M | −$123M | −$163M |
| Capital expenditure | $4.2M | $16.1M | $8.7M | $7.3M | $4.5M |
| Free cash flow | −$38.2M | −$148M | −$174M | −$130M | −$167M |
| FCF margin | — | — | — | −4,363.4% | −3,607.4% |
| Share count change | 391.5% | 161.2% | 168.4% | 30.4% | 25.4% |
| Debt and strength | |||||
| Cash and short-term investments | $254M | $286M | $41.6M | $182M | $178M |
| Shareholders' equity | −$156M | $316M | $133M | $153M | $121M |
| Current ratio | 4.7x | 11.1x | 2.5x | 5.6x | 4.8x |
| Returns and quality | |||||
| Return on equity | — | −152.2% | −88.2% | −136.9% | −146.8% |
| Return on tangible equity | — | −44.9% | −148.9% | −127.9% | −166.4% |
| Piotroski F-score | — | 2 | 1 | 4 | 3 |
| Altman Z'' | −1.7 | 7.6 | −10.1 | −7.2 | −9.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Prime Medicine, Inc. · PRME
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.67 a share, the company is worth $650M.
Source: SEC EDGAR XBRL filings (CIK 0001894562). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.